[go: up one dir, main page]

DE60209004D1 - Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate - Google Patents

Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate

Info

Publication number
DE60209004D1
DE60209004D1 DE60209004T DE60209004T DE60209004D1 DE 60209004 D1 DE60209004 D1 DE 60209004D1 DE 60209004 T DE60209004 T DE 60209004T DE 60209004 T DE60209004 T DE 60209004T DE 60209004 D1 DE60209004 D1 DE 60209004D1
Authority
DE
Germany
Prior art keywords
aminochinoline
derivatives
intermediate products
compounds use
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60209004T
Other languages
English (en)
Other versions
DE60209004T2 (de
Inventor
David B Damon
Robert Wayne Dugger
Robert William Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60209004D1 publication Critical patent/DE60209004D1/de
Application granted granted Critical
Publication of DE60209004T2 publication Critical patent/DE60209004T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60209004T 2001-04-30 2002-04-08 Verbindungen,die als zwischenstufen für cholesterylestertransferprotein(cetp)-inhibitoren verwendbar sind Expired - Fee Related DE60209004T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30
US287522P 2001-04-30
PCT/IB2002/001217 WO2002088069A2 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatives

Publications (2)

Publication Number Publication Date
DE60209004D1 true DE60209004D1 (de) 2006-04-13
DE60209004T2 DE60209004T2 (de) 2006-09-28

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60210265T Expired - Fee Related DE60210265T2 (de) 2001-04-30 2002-04-08 Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
DE60209004T Expired - Fee Related DE60209004T2 (de) 2001-04-30 2002-04-08 Verbindungen,die als zwischenstufen für cholesterylestertransferprotein(cetp)-inhibitoren verwendbar sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60210265T Expired - Fee Related DE60210265T2 (de) 2001-04-30 2002-04-08 Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren

Country Status (24)

Country Link
US (3) US6689897B2 (de)
EP (2) EP1383734B1 (de)
JP (2) JP3924250B2 (de)
KR (2) KR100591998B1 (de)
CN (3) CN1297541C (de)
AR (3) AR035963A1 (de)
AT (2) ATE316957T1 (de)
AU (1) AU2002253448B2 (de)
BR (2) BR0209238A (de)
CA (2) CA2445693A1 (de)
CZ (2) CZ20032900A3 (de)
DE (2) DE60210265T2 (de)
DK (2) DK1425270T3 (de)
ES (2) ES2259080T3 (de)
HU (2) HU225777B1 (de)
IL (2) IL157546A0 (de)
MX (2) MXPA03009936A (de)
PL (2) PL366700A1 (de)
PT (1) PT1425270E (de)
RU (2) RU2265010C2 (de)
TW (1) TWI250974B (de)
WO (2) WO2002088085A2 (de)
YU (2) YU84303A (de)
ZA (2) ZA200306600B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
KR20050055747A (ko) 2002-10-04 2005-06-13 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료용의 ｐｇｄ2 수용체 길항제
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1578415B1 (de) 2002-12-20 2008-09-10 Pfizer Products Inc. Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
EP1594843B1 (de) 2003-02-18 2013-05-22 Takasago International Corporation VERFAHREN ZUR HERSTELLUNG eines OPTISCH AKTIVEM beta-Aminosäurederivates
BRPI0407954A (pt) * 2003-03-17 2006-03-07 Kaneka Corp processo para a produção de derivado de amida de ácido (r)-3-[4-(trifluorometil) fenilamino]-pentanóico
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
CN1886124A (zh) 2003-09-26 2006-12-27 日本烟草产业株式会社 抑制残余脂蛋白产生的方法
US7749992B2 (en) * 2003-10-08 2010-07-06 Eli Lilly And Company Compounds and methods for treating dislipidemia
JP4839221B2 (ja) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Ｈｄｌを高める併用療法用複合物
WO2005100321A1 (en) * 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
RU2007135224A (ru) 2005-02-24 2009-03-27 Милленниум Фармасьютикалз, Инк. (Us) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
EP1896402A4 (de) * 2005-06-20 2010-07-28 Astrazeneca Ab Verfahren zur herstellung von (alkoxycarbonylamino)alkylsulfonaten
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
RU2597266C2 (ru) 2011-04-12 2016-09-10 Чхон Кхун Дан Фармасьютикал Корп. Циклоалкениларильные производные для ингибирования транспортного белка холестериновых эфиров
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
HUE033790T2 (en) 2013-01-31 2017-12-28 Chong Kun Dang Pharmaceutical Corp Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
CA2926010A1 (en) * 2013-11-11 2015-05-14 Lonza Ltd Method for preparation of cyano compounds of the 13th group with a lewis acid
SG11201701077XA (en) * 2014-08-12 2017-03-30 Dezima Pharma B V Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205037B (de) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
ES2257864T3 (es) 1998-07-10 2006-08-01 Massachusetts Institute Of Technology Ligandos para metales y procesos mejorados catalizados por metales basados en los mismos.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.

Also Published As

Publication number Publication date
AR035963A1 (es) 2004-07-28
IL157544A0 (en) 2004-03-28
IL157546A0 (en) 2004-03-28
CN1297541C (zh) 2007-01-31
KR100591998B1 (ko) 2006-06-22
WO2002088085A3 (en) 2004-03-25
US6706881B2 (en) 2004-03-16
RU2003131871A (ru) 2005-04-10
EP1425270B1 (de) 2006-03-29
ZA200306600B (en) 2004-08-25
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
KR100639745B1 (ko) 2006-10-30
HK1062294A1 (en) 2004-10-29
HUP0304041A3 (en) 2005-08-29
JP3924250B2 (ja) 2007-06-06
MXPA03009935A (es) 2004-01-29
DK1425270T3 (da) 2006-07-03
KR20040015200A (ko) 2004-02-18
CA2445693A1 (en) 2002-11-07
US20020177716A1 (en) 2002-11-28
MXPA03009936A (es) 2004-01-29
JP2004527556A (ja) 2004-09-09
WO2002088069A3 (en) 2003-02-20
RU2265010C2 (ru) 2005-11-27
WO2002088069A9 (en) 2003-12-04
US6689897B2 (en) 2004-02-10
WO2002088069A2 (en) 2002-11-07
BR0209291A (pt) 2004-07-13
EP1383734A2 (de) 2004-01-28
ATE321755T1 (de) 2006-04-15
US20030216576A1 (en) 2003-11-20
YU84403A (sh) 2006-08-17
CZ20032898A3 (cs) 2004-07-14
HUP0304039A3 (en) 2005-10-28
PT1425270E (pt) 2006-07-31
CA2445623A1 (en) 2002-11-07
ZA200306599B (en) 2004-10-22
US20030073843A1 (en) 2003-04-17
CN1529696A (zh) 2004-09-15
YU84303A (sh) 2006-05-25
EP1383734B1 (de) 2006-02-01
ES2259080T3 (es) 2006-09-16
DE60209004T2 (de) 2006-09-28
JP3924251B2 (ja) 2007-06-06
AU2002253448B2 (en) 2007-07-05
CN100357265C (zh) 2007-12-26
DK1383734T3 (da) 2006-05-15
CN1505609A (zh) 2004-06-16
US6600045B2 (en) 2003-07-29
ATE316957T1 (de) 2006-02-15
HUP0304039A2 (hu) 2004-03-29
WO2002088085A2 (en) 2002-11-07
CZ20032900A3 (cs) 2004-06-16
PL366700A1 (en) 2005-02-07
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
CN1680292A (zh) 2005-10-12
HUP0304041A2 (hu) 2004-04-28
PL366584A1 (en) 2005-02-07
ES2256461T3 (es) 2006-07-16
TWI250974B (en) 2006-03-11
JP2004531541A (ja) 2004-10-14
DE60210265T2 (de) 2006-10-12
RU2003131870A (ru) 2005-01-27
HU225777B1 (en) 2007-08-28
DE60210265D1 (de) 2006-05-18
EP1425270A2 (de) 2004-06-09
AR044706A2 (es) 2005-09-21
CN1267411C (zh) 2006-08-02

Similar Documents

Publication Publication Date Title
DE60209004D1 (de) Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
ATE323487T1 (de) Glukokinase beeinflussende verbindungen
ATE549329T1 (de) Chinazoline verbindungen
ATE368658T1 (de) Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
DE60112064D1 (de) Benzoamid-piperidin verbindungen als substanz p-antagonisten
ATE335426T1 (de) Ausziehführungsgarnitur für schubladen
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DE60317711D1 (de) Kationische porphyrin-derivate als antibakterielle mittel
DE50110649D1 (de) Zubereitung für restenoseprophylaxe
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
DK1412328T3 (da) Dolastatin-10-derivater
ATE400206T1 (de) Ausziehführungsgarnitur für schubladen
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
ATE396191T1 (de) Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden
ATE335477T1 (de) Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden
DE60239613D1 (de) Antibakterielle zusammensetzung für medizinische werkzeuge
DE60317684D1 (de) SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
DE602004028821D1 (de) Pyrrolidiniumderivative als liganden für den muscarinen m3-rezeptor
DE60137061D1 (de) Platin-verbindungen als antitumorwirkstoffe
DE60218213D1 (de) Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
ATE529419T1 (de) Chromanderivate als estrogene verbindungen
DE60324848D1 (de) Ausgleichsmechanismus für drehwelle
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva
DE60201463D1 (de) Indanon-Derivate als Duftstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee